

Prices listed correspond to *institutional rates only*; please contact the lab for insurance rates.

Genetic Test	Institutional Price (USD\$) June 2014	CPT codes 2014 (Current)	TAT **	Specimen Requirements
<b>Neurofibromatosis Type 1 - <i>NF1</i> and Legius syndrome – <i>SPRED1</i></b>				
<b>NF1/SPRED1 Combo Comprehensive (NFSP1) RNA/cDNA-based</b> sequencing and dosage (del/dup) analysis by MLPA and FISH (if a micro-deletion is identified) for the <i>NF1</i> gene in combination with <b>Comprehensive DNA-based</b> sequencing and dosage (del/dup) analysis for the <i>SPRED1</i> gene. For each patient, both <i>NF1</i> and <i>SPRED1</i> genes are analyzed comprehensively, but price depends on test result obtained.	\$1400 (NF1/SPRED1 negative)	81408, 81407, 88230, 81404	25 15 (RUSH <sup>†</sup> )	(1) 10 ml of whole blood in EDTA (purple topped) tubes  (Minimum of 3 ml for pediatric patients)  Blood samples must be received within 60-72 hours
	\$1200 (NF1 mutation identified)	81408, 81407, 88230		
	\$500 (NF1 TGD identified)	81407		
	\$400 (SPRED1 mutation identified)	81405, 81404		
<b>NF1 Comprehensive (NF11) RNA/cDNA-based</b> sequencing and dosage (del/dup) analysis by MLPA and FISH (if a micro-deletion is identified) for the <i>NF1</i> gene only. A reduced price is charged if a micro-deletion (TGD) is found during analysis.	\$1200	81408, 81407, 88230	25 15 (RUSH <sup>†</sup> )	
	\$500 (NF1 TGD identified)	81407		
<b>NF1 DNA (NF1D) DNA-based</b> sequencing and dosage (del/dup) analysis by MLPA for the <i>NF1</i> gene starting from a DNA sample or from a blood sample that arrived >72 hours after blood draw.  **Please note: this is currently not the preferred method of NF1 testing for our lab, please contact us for more details**	\$1800	81407, 81408	35	(1) 10 ml of whole blood in EDTA (purple topped) tubes  (2) DNA sample
<b>SPRED1 Comprehensive (SPD1) DNA-based</b> sequencing and dosage (del/dup) analysis by MLPA for the <i>SPRED1</i> gene only. A reduced price is charged if a pathogenic mutation is found during sequencing.	\$650	81405, 81404	15	Applicable for those samples that cannot be received within 60-72 hours after blood draw
	\$400 (mutation identified during sequencing)	81405		
<b>NF1/SPRED1 Known Mutation (KT2) Targeted</b> detection of a specific, previously known, <i>NF1</i> and/or <i>SPRED1</i> mutation in at-risk family members by sequence, MLPA, and/or FISH analysis  Note: FISH analysis is performed in the UAB Cytogenetic Laboratory, directed by Prof. Dr. A. Carroll	\$250	81403	15	(1) 1 ml whole blood in EDTA (purple topped) tubes  (2) Buccal swab sample for sequence analysis only  (3) DNA sample
<b>NF1 or SPRED1 Prenatal (PT2) Targeted</b> detection of a specific, previously known, <i>NF1</i> or <i>SPRED1</i> mutation (includes maternal cell contamination (MCC <sup>†</sup> ) analysis)	\$750	81403, 81265	6	(1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (minimum 10 ml fluid) (3) 2 T25 flasks of cultured CVS (>70% confluent) (4) 2 T25 flasks of cultured amniocytes. (>70% confluent)  Please also send 1-5 ml of blood or buccal swab sample from mother for MCC studies.

**UAB Medical Genomics Laboratory**

Ph. (205) 934-5562 Fax (205) 996-2929

[www.genetics.uab.edu/medgenomics](http://www.genetics.uab.edu/medgenomics)

Genetic Test	Institutional Price (USD\$) June 2014	CPT codes 2014 (Current)	TAT **	Specimen Requirements
<b>NF1 CALs/NFs (NF14N) Comprehensive RNA/cDNA-based NF1</b> sequencing and dosage (del/dup) analysis on <i>cultured</i> neural crest derived cells from affected body regions (i.e. CAL-spots and/or neurofibromas) for possible segmental/mosaic NF1 cases <b>**Please note:</b> it is required to contact the laboratory at 205-934-5562 or email medgenomics@uabmc.edu <b>in advance</b> of sending specimens for this testing option**	\$2600	88233(x2), 81408, 81407, 81402(x2)	120	Dependent on size and quality of the tissue specimen received  <b>(1)</b> 2-3 5mm punch biopsies from CAL-spots. Special transport media required for shipping: contact us at 205-934-5562 <b>(2)</b> minimum 3 separate fresh neurofibromas. Special transport media required for shipping: contact us at 205-934-5562
<b>NF1 CALs (NF14C) Comprehensive RNA/cDNA-based NF1</b> sequencing and dosage (del/dup) analysis with reflexive <b>DNA-based SPRED1</b> sequencing and dosage (del/dup) analysis on <i>cultured</i> melanocytes from café-au-lait spots in affected body regions for possible segmental/mosaic NF1 and/or Legius syndrome cases with pigmentary findings only <b>**Please note:</b> it is required to contact the laboratory at 205-934-5562 or email medgenomics@uabmc.edu <b>in advance</b> of sending specimens for this testing option**	\$2600	88233, 81408, 81407, 81405, 81404	120	
<b>Neurofibromatosis Type 2 - NF2</b>				
<b>NF2 Comprehensive (NF21) RNA/cDNA-based</b> sequencing and dosage (del/dup) analysis. A reduced price is charged if a pathogenic mutation is found during sequencing. <b>Blood samples must be received within 60-72 hours</b>	\$1100	81406, 81405, 88230	25	<b>(1)</b> 10 ml of whole blood in EDTA (purple topped) tubes. (Minimum of 3 ml for pediatric patients)  <b>(2)</b> DNA sample
	\$800 (mutation identified during sequencing)	81406, 88230	15 (RUSH <sup>†</sup> )	
<b>NF2 DNA (NF2D) DNA-based</b> sequencing and dosage (del/dup) analysis by MLPA for the <b>NF2</b> gene starting from a DNA sample or from a blood sample that arrived >72 hours after blood draw. A reduced price is charged if a pathogenic mutation is found during sequencing.	\$1100	81406, 81405	25	<b>(2)</b> DNA sample
	\$800 (mutation identified during sequencing)	81406	15 (RUSH <sup>†</sup> )	
<b>NF2 Known Mutation (KT2) Targeted</b> detection of a specific, previously known, <b>NF2</b> mutation in at risk family members by sequence, MLPA, and/or FISH analysis <b>**Please note:</b> FISH analysis is performed in the UAB Cytogenetic Laboratory, directed by Prof. Dr. A. Carroll **	\$250	81403	10	<b>(1)</b> 1 ml whole blood in EDTA (purple topped) tubes <b>(2)</b> Buccal swab sample for sequence analysis only <b>(3)</b> DNA sample
<b>NF2 Prenatal (PT2) Targeted</b> detection of a specific, previously known, <b>NF2</b> mutation (includes maternal cell contamination (MCC <sup>†</sup> ) analysis)	\$750	81403, 81265	6	<b>(1)</b> Direct CVS, (minimum 10 mg pure villi) <b>(2)</b> Direct amniotic fluid (min. 10 ml fluid) <b>(3)</b> 2 T25 flasks of cultured CVS (>70% confluent) <b>(4)</b> 2 T25 flasks of cultured amniocytes. (>70% confluent) Please also send 1-5 ml of blood or buccal swab sample from mother for maternal contamination studies.
<b>NF2 Tumor (NF24) Comprehensive gDNA-based NF2 testing</b> on a minimum of 2 <b>different</b> tumor specimens by direct sequencing and dosage (del/dup) analysis by MLPA of the <b>NF2</b> gene. Any mutations found in the tumor tissue will be confirmed in blood at no additional cost if the blood sample is submitted the same week as the tumor specimen.	\$1400	81405, 81406, 81403(x2)	25	<b>(1)</b> Tumor block <b>(2)</b> Flash frozen tumor sent on dry ice <b>(3)</b> Fresh tumor biopsy, immersed in culture media (PBS/RPMI) <b>(4)</b> Blood specimen for confirmation at no additional charge if sent within a week of the tumor specimen

### UAB Medical Genomics Laboratory

Ph. (205) 934-5562 Fax (205) 996-2929

[www.genetics.uab.edu/medgenomics](http://www.genetics.uab.edu/medgenomics)

Genetic Test	Institutional Price (USD\$) June 2014	CPT codes 2014 (Current)	TAT **	Specimen Requirements
<b>Schwannomatosis/Rhabdoid Tumor Predisposition Syndrome (RTPS) - <i>SMARCB1</i> and <i>LZTR1</i></b>				
<b>SMARCB1 DNA (SB1D)</b> <u>DNA-based</u> sequencing <i>and</i> dosage (del/dup) analysis by MLPA for the <i>SMARCB1</i> gene starting from a DNA sample or from a blood sample that arrived >72 hours after blood draw.	\$800	81405, 81404	25 15 (RUSH <sup>†</sup> )	(1) 10 ml of whole blood in EDTA (purple topped) tubes. (Minimum of 3 ml for pediatric patients) (2) DNA sample
<b>LZTR1 Sequencing on Blood (LZTR1)</b> <u>DNA-based</u> sequencing for the <i>LZTR1</i> gene starting from a DNA sample or from a blood sample that arrived >72 hours after blood draw.	\$800	81406	20	(1) 10 ml of whole blood in EDTA (purple topped) tubes. (Minimum of 3 ml for pediatric patients) (2) DNA sample
<b>LZTR1 or SMARCB1 Targeted (KT2)</b> <u>Targeted</u> detection of a specific, previously known, <i>SMARCB1</i> or <i>LZTR1</i> mutation in at risk family members by sequence, MLPA, and/or FISH analysis <b>**Please note:</b> FISH analysis is performed in the UAB Cytogenetic Laboratory, directed by Prof. Dr. A. Carroll**	\$250	81403	10	(1) 1 ml whole blood in EDTA (purple topped) tubes (2) Buccal swab sample for sequence analysis only (3) DNA sample
<b>SMARCB1 Prenatal (PT2)</b> <u>Targeted</u> detection of a specific, previously known, <i>SMARCB1</i> mutation (includes maternal cell contamination (MCC) <sup>†</sup> analysis)	\$750	81403, 81265	6	(1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (minimum 10 ml fluid) (3) 2 T25 flasks of cultured CVS (>70% confluent) (4) 2 T25 flasks of cultured amniocytes. (>70% confluent)  Please also send 1-5 ml of blood or buccal swab sample from mother for maternal contamination studies.
<b>SMARCB1 Schwannoma (SB14Sch)</b> <u>Comprehensive DNA-based</u> testing for Schwannomatosis on a minimum of 2 <b>different</b> tumor specimens by direct sequencing <i>and</i> dosage (del/dup) analysis by MLPA of both the <i>SMARCB1</i> and <i>NF2</i> genes. Any mutations found in the tumor tissue will be confirmed in blood at no additional cost if the blood sample is submitted the same week as the tumor specimen.	\$2200	81405(x2), 81404, 81406, 81402, 81403	30	(1) Tumor block (2) Flash frozen tumor sent on dry ice (3) Fresh tumor biopsy, immersed in culture media (PBS/RPMI) (4) Blood specimen for confirmation at no additional charge if sent within a week of the tumor specimen
<b>LZTR1 Reflexive testing on tumor (SB14Sch)</b> <u>DNA-based</u> testing for Schwannomatosis on tumor specimens previously received by the laboratory for <i>SMARCB1</i> analysis which revealed no identifiable first hit. This testing includes direct sequencing of the <i>LZTR1</i> gene. Any mutations found in the tumor tissue will be confirmed in blood at no additional cost.	\$800	81406	20	(1) Tumor block (2) Flash frozen tumor sent on dry ice (3) Fresh tumor biopsy, immersed in culture media (PBS/RPMI) (4) Blood specimen for confirmation at no additional charge if sent within a week of the tumor specimen
<b>SMARCB1 Rhabdoid (SB14RT)</b> <u>Comprehensive DNA-based</u> testing for RTPS on a tumor specimen by direct sequencing <i>and</i> dosage (del/dup) analysis by MLPA of the <i>SMARCB1</i> gene. Any mutations found in the tumor tissue will be confirmed in blood at no additional cost if the blood sample is submitted the same week as the tumor specimen.	\$1400	81405, 81404, 81402, 81403 (x2)	25	(1) Tumor block (2) Flash frozen tumor sent on dry ice (3) Fresh tumor biopsy, immersed in culture media (PBS/RPMI) (4) Blood specimen for confirmation at no additional charge if sent within a week of the tumor specimen
<b>Tuberous Sclerosis Complex –TSC1/TSC2</b>				
<b>TSC1 Sequencing only (TSC1-S)</b> <u>DNA-based</u> sequencing for the <i>TSC1</i> gene	\$1000	81406	20	(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes (2) DNA sample

### UAB Medical Genomics Laboratory

Ph. (205) 934-5562 Fax (205) 996-2929

[www.genetics.uab.edu/medgenomics](http://www.genetics.uab.edu/medgenomics)

Genetic Test	Institutional Price (USD\$) June 2014	CPT codes 2014 (Current)	TAT **	Specimen Requirements
<b>TSC1 MLPA only (TSC1-M)</b> <u>DNA-based</u> dosage (del/dup) analysis by MLPA for the <b>TSC1</b> gene	\$500	81405	20	(1) 1 ml whole blood in EDTA (purple topped) tubes (2) DNA sample
<b>TSC2 Sequencing only (TSC2-S)</b> <u>DNA-based</u> sequencing for the <b>TSC2</b> gene	\$1400	81407	20	(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes (2) DNA sample
<b>TSC2 MLPA only (TSC2-M)</b> <u>DNA-based</u> dosage (del/dup) analysis by MLPA for the <b>TSC2</b> gene	\$500	81406	20	(1) 1 ml whole blood in EDTA (purple topped) tubes (2) DNA sample
<b>Complete Tuberous Sclerosis Panel Testing (TSCP)</b> <u>DNA-based</u> sequencing and dosage (del/dup) analysis by MLPA for the <b>TSC1</b> and <b>TSC2</b> gene	\$2400	81408, 81407	20	(1) 1 ml whole blood in EDTA (purple topped) tubes (2) DNA sample
<b>TSC Known Mutation (KT2)</b> <u>Targeted</u> detection of a specific, previously known, mutation in any of the genes mentioned above in at risk family members by sequence analysis	\$250	81403	10	(1) 1 ml whole blood in EDTA (purple topped) tubes (2) DNA sample
<b>TSC Prenatal (PT2)</b> <u>Targeted</u> detection of a specific, previously known, : <b>TSC1</b> or <b>TSC2</b> mutation (includes maternal cell contamination (MCC) <sup>†</sup> analysis)	\$750	81322, 81265	6	(1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (minimum 10 ml fluid) (3) 2 T25 flasks of cultured CVS (>70% confluent) (4) 2 T25 flasks of cultured amniocytes. (>70% confluent) Please also send 1-5 ml of blood or buccal swab sample from mother for maternal contamination studies.
<b>Ras-o-pathy Panels – Noonan, Cardio-facio-cutaneous (CFC), and LEOPARD syndromes</b>				
<b>Noonan syndrome panel (NNP)</b> <u>DNA-based</u> sequencing of 13 genes associated with a Noonan or Noonan-like phenotype: <b>PTPN11, SOS1, RAF1, KRAS, NRAS, SHOC2, CBL, BRAF, MAP2K1, MAP2K2, HRAS, RIT1, and SPRED1</b> . In addition, this testing also includes dosage (del/dup) analysis by MLPA for the <b>SPRED1</b> gene.	\$1500	81408, 81404	20	(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes
<b>Cardio-facio-cutaneous (CFC) syndrome panel (CFCP)</b> <u>DNA-based</u> sequencing of 4 genes associated with <b>CFC: BRAF, MAP2K1, MAP2K2, and KRAS</b>	\$1100	81407	20	(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes
<b>LEOPARD syndrome panel (LPDP)</b> <u>DNA-based</u> sequencing of 3 genes associated with LEOPARD syndrome: <b>PTPN11, RAF1, and BRAF</b>	\$1100	81407	20	(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes
<b>Ras-o-pathy Single Gene Testing</b>				
<b>Costello syndrome (CST1)</b> <u>DNA-based</u> sequencing of the <b>HRAS</b> gene	\$300	81404	15	(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes
<b>Metachondromatosis (MTM1)</b> <u>DNA-based</u> sequencing of the <b>PTPN11</b> gene	\$900	81406	15	(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes

### UAB Medical Genomics Laboratory

Ph. (205) 934-5562 Fax (205) 996-2929

[www.genetics.uab.edu/medgenomics](http://www.genetics.uab.edu/medgenomics)

Genetic Test	Institutional Price (USD\$) June 2014	CPT codes 2014 (Current)	TAT **	Specimen Requirements
<b>Single Gene Sequencing (SGS1) DNA-based</b> sequencing of any single gene offered on the Ras-o-pathy panels: <i>PTPN11, SOS1, RAF1, KRAS, NRAS, SHOC2, CBL, BRAF, MAP2K1, MAP2K2, SPRED1, RIT1, and HRAS</i> <b>**Please note:</b> it is required to contact the laboratory at 205-934-5562 or email medgenomics@uabmc.edu in <b>advance</b> of sending specimens for this testing option**	\$900 (PTPN11)	81406	20	(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes
	\$550 (SOS1, RAF1, BRAF, MAP2K1, MAP2K2)	81406		
	\$300 (RIT1, KRAS, NRAS, CBL, HRAS)	81404		
	\$250 (SHOC2)	81403		
	\$400/\$650 (SPRED1 Seq and del/dup)	Please refer to page 1 for more details.		
<b>Ras-o-pathy Known Mutation (KT2) Targeted</b> detection of a specific, previously known, mutation in any of the genes mentioned above in at risk family members by sequence analysis	\$250	81403	10	(1) 1 ml whole blood in EDTA (purple topped) tubes (2) DNA sample
<b>Ras-o-pathy Prenatal (PT2) Targeted</b> detection of a specific, previously known, : <i>PTPN11, SOS1, RAF1, KRAS, NRAS, SHOC2, CBL, BRAF, MAP2K1, MAP2K2, SPRED1, RIT1, or HRAS</i> mutation (includes maternal cell contamination (MCC) <sup>†</sup> analysis)	\$750	81322, 81265	6	(1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (minimum 10 ml fluid) (3) 2 T25 flasks of cultured CVS (>70% confluent) (4) 2 T25 flasks of cultured amniocytes. (>70% confluent) Please also send 1-5 ml of blood or buccal swab sample from mother for maternal contamination studies.
<b>PTEN Hamartoma Tumor Syndrome / Macrocephaly-Autism Syndrome – PTEN</b>				
<b>PTEN Comprehensive (PTEN1) DNA-based</b> testing by sequencing <i>and</i> dosage (del/dup) analysis by MLPA for the <i>PTEN</i> gene. A reduced price is charged if a pathogenic mutation is found during sequencing	\$1100	81323, 81321	25	(1) 10 ml of whole blood in EDTA (purple topped) tubes. (Minimum of 3 ml for pediatric patients; For add-on Fragile X testing for pediatric patients, we require a minimum of 5 ml) (2) DNA sample
	\$800 (if mutation identified during sequencing)	81321		
<b>PTEN Known Mutation (KT2) Targeted</b> detection of a specific, previously known, <i>PTEN</i> mutation in at risk family members by sequence and/or MLPA analysis	\$250	81322	10	(1) 1 ml whole blood in EDTA (purple topped) tubes (2) DNA sample
<b>PTEN Prenatal (PT2) Targeted</b> detection of a specific, previously known, <i>PTEN</i> mutation (includes maternal cell contamination (MCC) <sup>†</sup> analysis)	\$750	81322, 81265	6	(1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (minimum 10 ml fluid) (3) 2 T25 flasks of cultured CVS (>70% confluent) (4) 2 T25 flasks of cultured amniocytes. (>70% confluent) Please also send 1-5 ml of blood or buccal swab sample from mother for maternal contamination studies.
<b>Von-Hippel Lindau Syndrome – VHL</b>				
<b>VHL Comprehensive (VHL1) DNA-based</b> sequencing <i>and</i> dosage (del/dup) analysis by MLPA for the <i>VHL</i> gene. A reduced price is charged if a pathogenic mutation is found during sequencing	\$650	81404, 81403	15	(1) Minimum of 5 mL whole blood in EDTA (purple topped) tubes (2) DNA sample
	\$400 (if mutation identified during sequencing)	81404		

### UAB Medical Genomics Laboratory

Ph. (205) 934-5562 Fax (205) 996-2929

[www.genetics.uab.edu/medgenomics](http://www.genetics.uab.edu/medgenomics)

Genetic Test	Institutional Price (USD\$) June 2014	CPT codes 2014 (Current)	TAT **	Specimen Requirements
<b>VHL Known Mutation (KT2) Targeted</b> detection of a specific, previously known, <b>VHL</b> mutation in at risk family members by sequence and/or MLPA analysis	\$250	81403	10	(1) 1 ml whole blood in EDTA (purple topped) tubes (2) DNA sample
<b>VHL Prenatal (PT2) Targeted</b> detection of a specific, previously known, <b>VHL</b> mutation (includes maternal cell contamination (MCC) <sup>†</sup> analysis)	\$750	81403, 81265	6	(1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (minimum 10 ml fluid) (3) 2 T25 flasks of cultured CVS (>70% confluent) (4) 2 T25 flasks of cultured amniocytes. (>70% confluent) Please also send 1-5 ml of blood or buccal swab sample from mother for maternal contamination studies.
<b>Autosomal Recessive Polycystic Kidney Disease - PKHD1</b>				
<b>ARPKD Comprehensive (PKD1) DNA-based</b> sequencing of the entire <b>PKHD1</b> longest open reading frame <i>and</i> dosage (del/dup) analysis by MLPA, detecting >82% of mutations. This includes automatically reflexing through Tiers 1-3: <b>Tier 1:</b> Sequencing of 23 exons which will detect 2 clear pathogenic mutations in ~64% of ARPKD patients <b>Tier 2:</b> Sequencing of the remaining exons of the entire longest open reading frame <i>and</i> targeted analysis for a deep intronic splicing alteration in intron 46 <b>Tier 3:</b> Dosage (del/dup) analysis by MLPA/qPCR A reduced price is charged based on which tiers are necessary to identify two clear pathogenic mutations in a proband.	\$2600 (Tiers 1+2+3 necessary)	81408, 81407	20  8 for Tier1+2 RUSH	(1) 5 ml whole blood in EDTA (purple tubes) (2) biopsy from skin/liver/spleen. (fresh or frozen) (3) 2 T25 flasks of cultured cells
	\$2200 (Tiers 1+2 necessary)	81408		
	\$1100 (only Tier 1 was necessary)	81406		
<b>ARPKD Sequencing (PKDS) DNA-based</b> sequencing-only of the entire <b>PKHD1</b> longest open reading frame, detecting ~80% of mutations <b>Tier 1:</b> Sequencing of 23 exons which will detect 2 clear pathogenic mutations in ~64% of ARPKD patients <b>Tier 2:</b> Sequencing of the remaining exons of the entire longest open reading frame <i>and</i> targeted analysis for a deep intronic splicing alteration IVS46+653 A>G (Tier 1+2 <b>can</b> be ordered as a standalone test)	\$2200 (Tiers 1+2 necessary) \$3200 (for RUSH):	81408		
	\$1100 (only Tier 1 is necessary)	81406		
<b>ARPKD Known Mutation (KT2) Targeted</b> detection of specific, previously known, <b>PKHD1</b> mutation(s) in family members by sequence and/or MLPA analysis	Sequencing 1 exon: \$250	1 exon: 81403	15	(1) 5 ml whole blood in EDTA (purple topped) tubes (2) Buccal swab sample
	Sequencing 2 exons: \$340	2 exons: 81403(x2)		
	MLPA: \$250	MLPA: 81407		
<b>ARPKD Prenatal Targeted (PT2) Targeted</b> detection of specific, previously known, <b>PKHD1</b> mutations (includes maternal cell contamination (MCC) <sup>†</sup> analysis)	\$1000	81403(x2), 81265	6	(1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (minimum 10 ml fluid) (3) 2 T25 flasks of cultured CVS. (>70% confluent) (4) 2 T25 flasks of cultured amniocytes. (>70% confluent) Please also send 1-5 ml of blood or buccal swab sample from mother for maternal contamination studies.

### UAB Medical Genomics Laboratory

Ph. (205) 934-5562 Fax (205) 996-2929

[www.genetics.uab.edu/medgenomics](http://www.genetics.uab.edu/medgenomics)

<b>ARPKD Informativity (PKDL) Haplotype analysis</b> by PCR of 7 markers within and flanking the <b>PKHD1</b> disease interval on chromosome 6p21-cen	\$400/ individual tested	81265	20	Please send samples from the parents and their children for informativity results <b>(1)</b> 10ml of whole blood in EDTA (purple topped) tubes. (2 ml minimum for pediatric patients) <b>(2)</b> Paraffin-embedded tissue blocks or whole tissue from affected individual <b>(3)</b> For prenatal samples, please send 2 T25 flasks of cultured CVS or 2 T25 flasks of cultured amniocytes Please also send 1-5 ml of blood or buccal swab sample from mother for maternal contamination studies.
<b>ARPKD Prenatal Linkage (PKDPL) Haplotype analysis</b> by PCR of 7 markers within and flanking the <b>PKHD1</b> disease interval on chromosome 6p21-cen as a prenatal test (includes maternal cell contamination (MCC) <sup>†</sup> analysis)	\$500/ individual tested	81265	6	

Note: A **comprehensive test** is a direct test that uses multiple complementary assays to detect all types of lesions within the entire coding region. A **targeted test** is a test that solely detects a previously characterized specific mutation within the family. A **prenatal test** is a test that detects a previously characterized specific mutation within a family on a prenatal sample and testing includes maternal cell contamination analysis.

\*Targeting testing for parents is free of charge if both parents of the proband are submitted during the same week as the proband.

\*\*Turn-around time is **working days** starting from the day after receipt of sample.

<sup>†</sup> Maternal Cell Contamination Analysis is abbreviated as MCC and is performed as a part of prenatal testing.

<sup>‡</sup> RUSH fee for *NF1*, *NF2*, and *SMARCB1* is an additional \$600